Although another PDE targeting compound has just completed phase 2 clinical trials in patients with FXS, the use of EEG as an outcome measure for the effectiveness of these drugs in humans has not yet been fully explored. This evidence concerns the gene ALDH7A1 and fragile X syndrome.